Myeloid cells contribute to the immunosuppressive tumour microenvironment and can be responsible for resistance to cancer immunotherapy. Here, the authors describe the current therapies that aim to modulate the functional activities of myeloid cell populations, impacting their recruitment, survival and activity in the tumour microenvironment, acting at the level of cell surface receptors, signalling pathways, epigenetic machinery and metabolic regulators.
- Sangeeta Goswami
- Swetha Anandhan
- Padmanee Sharma
